Literature DB >> 27993895

Mutation patterns in small cell and non-small cell lung cancer patients suggest a different level of heterogeneity between primary and metastatic tumors.

Ali Saber1, T Jeroen N Hiltermann2, Klaas Kok3, M Martijn Terpstra3, Kim de Lange3, Wim Timens1, Harry J M Groen2, Anke van den Berg1.   

Abstract

Several studies have shown heterogeneity in lung cancer, with parallel existence of multiple subclones characterized by their own specific mutational landscape. The extent to which minor clones become dominant in distinct metastasis is not clear. The aim of our study was to gain insight in the evolution pattern of lung cancer by investigating genomic heterogeneity between primary tumor and its distant metastases. Whole exome sequencing (WES) was performed on 24 tumor and five normal samples of two small cell lung carcinoma (SCLC) and three non-SCLC (NSCLC) patients. Validation of somatic variants in these 24 and screening of 33 additional samples was done by single primer enrichment technology. For each of the three NSCLC patients, about half of the mutations were shared between all tumor samples, whereas for SCLC patients, this percentage was around 95. Independent validation of the non-ubiquitous mutations confirmed the WES data for the vast majority of the variants. Phylogenetic trees indicated more distance between the tumor samples of the NSCLC patients as compared to the SCLC patients. Analysis of 30 independent DNA samples of 16 biopsies used for WES revealed a low degree of intra-tumor heterogeneity of the selected sets of mutations. In the primary tumors of all five patients, variable percentages (19-67%) of the seemingly metastases-specific mutations were present albeit at low read frequencies. Patients with advanced NSCLC have a high percentage of non-ubiquitous mutations indicative of branched evolution. In contrast, the low degree of heterogeneity in SCLC suggests a parallel and linear model of evolution.
© The Author 2017. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Year:  2017        PMID: 27993895     DOI: 10.1093/carcin/bgw128

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  18 in total

1.  Pretreatment metabolic tumour volume in stage IIIA/B non-small-cell lung cancer uncovers differences in effectiveness of definitive radiochemotherapy schedules: analysis of the ESPATUE randomized phase 3 trial.

Authors:  Maja Guberina; Wilfried Eberhardt; Martin Stuschke; Thomas Gauler; Clemens Aigner; Martin Schuler; Georgios Stamatis; Dirk Theegarten; Walter Jentzen; Ken Herrmann; Christoph Pöttgen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-02-01       Impact factor: 9.236

2.  Predictors of prognosis of synchronous brain metastases in small-cell lung cancer patients.

Authors:  Sumanth P Reddy; Jonathan E Dowell; Edward Pan
Journal:  Clin Exp Metastasis       Date:  2020-06-04       Impact factor: 5.150

3.  Applications of CRISPR/Cas technology against drug-resistant lung cancers: an update.

Authors:  Mayank Chaudhary; Pooja Sharma; Tapan Kumar Mukherjee
Journal:  Mol Biol Rep       Date:  2022-09-12       Impact factor: 2.742

4.  Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE.

Authors:  Josephine Graf; Ulrich-Frank Pape; Henning Jann; Timm Denecke; Ruza Arsenic; Winfried Brenner; Marianne Pavel; Vikas Prasad
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-08-14       Impact factor: 9.236

Review 5.  CRISPR/Cas9 for overcoming drug resistance in solid tumors.

Authors:  Ali Saber; Bin Liu; Pirooz Ebrahimi; Hidde J Haisma
Journal:  Daru       Date:  2019-01-21       Impact factor: 3.117

6.  Comparative expression analysis in small cell lung carcinoma reveals neuroendocrine pattern change in primary tumor versus lymph node metastases.

Authors:  Zoltan Lohinai; Zsolt Megyesfalvi; Kenichi Suda; Tunde Harko; Shengxiang Ren; Judit Moldvay; Viktoria Laszlo; Christopher Rivard; Balazs Dome; Fred R Hirsch
Journal:  Transl Lung Cancer Res       Date:  2019-12

Review 7.  Lung carcinogenesis and fibrosis taken together: just coincidence?

Authors:  Ioanna Giopanou; Kristina A M Arendt; Georgios T Stathopoulos
Journal:  Curr Opin Pulm Med       Date:  2017-07       Impact factor: 3.155

8.  Genetic heterogeneity of primary lesion and metastasis in small intestine neuroendocrine tumors.

Authors:  Dirk Walter; Patrick N Harter; Florian Battke; Ria Winkelmann; Markus Schneider; Katharina Holzer; Christine Koch; Jörg Bojunga; Stefan Zeuzem; Martin Leo Hansmann; Jan Peveling-Oberhag; Oliver Waidmann
Journal:  Sci Rep       Date:  2018-02-28       Impact factor: 4.379

9.  Integrated omics and gene expression analysis identifies the loss of metabolite-metabolite correlations in small cell lung cancer.

Authors:  Li Yu; Kefeng Li; Zhaoguo Xu; Guoyuan Cui; Xiaoye Zhang
Journal:  Onco Targets Ther       Date:  2018-07-06       Impact factor: 4.147

10.  Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment.

Authors:  Marzia Del Re; Paola Bordi; Iacopo Petrini; Eleonora Rofi; Francesca Mazzoni; Lorenzo Belluomini; Enrico Vasile; Giuliana Restante; Francesco Di Costanzo; Alfredo Falcone; Antonio Frassoldati; Ron H N van Schaik; Christi M J Steendam; Antonio Chella; Marcello Tiseo; Riccardo Morganti; Romano Danesi
Journal:  Oncotarget       Date:  2017-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.